What is Invenra?
Invenra specializes in the discovery and development of bispecific and trispecific antibodies, leveraging its proprietary B-Body Platform to address unmet medical needs. By providing rapid bispecific discovery and advanced antibody expression services, the company serves as a vital partner to biopharmaceutical firms seeking to enhance their therapeutic pipelines. The firm's focus on high-throughput, high-fidelity antibody engineering distinguishes it as a key innovator in the field of protein therapeutics, enabling the creation of molecules with superior efficacy and safety profiles compared to traditional monoclonal approaches.
How much funding has Invenra raised?
Invenra has raised a total of $38.6M across 9 funding rounds:
Private Equity
$3M
Private Equity
$2M
Private Equity
$2M
Private Equity
$3M
Private Equity
$2.9M
Series A
$17.1M
Series B
$7M
Debt
$350K
Private Equity (2013): $3M, investors not publicly disclosed
Private Equity (2015): $2M, investors not publicly disclosed
Private Equity (2015): $2M, investors not publicly disclosed
Private Equity (2016): $3M, investors not publicly disclosed
Private Equity (2017): $2.9M, investors not publicly disclosed
Series A (2018): $17.1M led by Venture Investors and Wisconsin Investment Partners
Series B (2019): $7M, investors not publicly disclosed
Debt (2020): $350K featuring PPP
Key Investors in Invenra
Venture Investors
A venture capital firm specializing in early-stage investments within the healthcare and life sciences sectors, providing strategic guidance to high-growth biotech companies.
Wisconsin Investment Partners
An angel investment group focused on supporting innovative startups in the Midwest, with a particular emphasis on technology and life science ventures.
PPP
Public-Private Partnership
What's next for Invenra?
With the recent infusion of capital, Invenra is well-positioned to scale its B-Body Platform and expand its collaborative research efforts. The strategic allocation of these funds will likely prioritize the acceleration of internal drug discovery programs and the enhancement of its antibody expression capabilities. As the company navigates the complexities of clinical development, the focus remains on securing high-value partnerships and advancing its lead candidates through the regulatory pipeline. This financial stability provides the necessary runway to sustain long-term research objectives and maintain a competitive edge in the rapidly evolving biopharmaceutical market.
See full Invenra company page
